Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$7.10 | -$0.41 | Beat |
| May 5, 2026 | -$2.66 | -$2.66 | Beat |
| Mar 17, 2026 | -$2.66 | -$1.75 | Beat |
| Nov 12, 2025 | -$121.80 | -$0.30 | Beat |
| Aug 5, 2025 | – | -$0.11 | |
| May 6, 2025 | – | -$0.56 |